The New Stealth Drug on the Street: A Narrative Review of Xylazine as a Street Drug.

"tranq" alpha-adrenergic receptor fentanyl overdose polysubstance abuse sedatives street drugs xylazine

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 06 04 2023
accepted: 25 06 2023
medline: 28 7 2023
pubmed: 28 7 2023
entrez: 28 7 2023
Statut: epublish

Résumé

Xylazine is an alpha-adrenergic receptor agonist approved for use only in animals with a prescription from a veterinarian. It is a powerful sedative that is slowly infiltrating the recreational street drug scene and is often used by polysubstance abusers. Known as "tranq," it can be fatal, and xylazine-induced toxicity cannot be reversed with naloxone or nalmefene. Due to its vasoconstrictive effects, chronic use of xylazine is associated with necrotic skin lesions and general deterioration of health. Since xylazine is not approved for human use and is not scheduled as a controlled substance, there are no human studies to provide evidence of drug-drug interactions, lethal doses, or reversal protocols. Xylazine is available online without a prescription. Street drug users may take xylazine knowingly or unknowingly, as it is often combined with other illicit substances such as fentanyl. There are no rapid tests for xylazine, although there are specialty tests that can be ordered. Xylazine represents a major threat to street drug users and another challenge to emergency healthcare workers, first responders, and others who care for those who have taken this "new" street drug.

Identifiants

pubmed: 37503500
doi: 10.7759/cureus.40983
pmc: PMC10370501
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e40983

Informations de copyright

Copyright © 2023, Pergolizzi Jr et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Cureus. 2022 Aug 19;14(8):e28160
pubmed: 36148197
Clin Toxicol (Phila). 2007;45(3):309-11
pubmed: 17453890
Am J Public Health. 2022 Aug;112(8):1212-1216
pubmed: 35830662
Clin Toxicol (Phila). 2022 Aug;60(8):892-901
pubmed: 35442125
Forensic Sci Int. 2021 Mar;320:110705
pubmed: 33529997
J Addict Med. 2022 Sep-Oct 01;16(5):595-598
pubmed: 35020700
Drug Alcohol Depend. 2022 Apr 1;233:109380
pubmed: 35247724
Harm Reduct J. 2021 Oct 13;18(1):104
pubmed: 34645480
Am J Vet Res. 1990 Apr;51(4):556-60
pubmed: 2327614
Psychosomatics. 2016 Sep-Oct;57(5):529-33
pubmed: 27480943
J Emerg Med. 2006 May;30(4):407-10
pubmed: 16740450
Subst Abuse Treat Prev Policy. 2011 Apr 11;6:7
pubmed: 21481268
J Urban Health. 2012 Jun;89(3):519-26
pubmed: 22391983
Am J Forensic Med Pathol. 2021 Mar 1;42(1):9-11
pubmed: 33031124
J Emerg Med. 2016 Oct;51(4):389-393
pubmed: 27473444
Vet Hum Toxicol. 2004 Dec;46(6):324-5
pubmed: 15587251
Postgrad Med J. 1990 Mar;66(773):244-5
pubmed: 2362897
MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1303-1304
pubmed: 34529638
Drug Alcohol Depend. 2008 Aug 1;96(3):290-3
pubmed: 18472231
J Forensic Leg Med. 2021 Apr;79:102151
pubmed: 33773270
Inj Prev. 2021 Aug;27(4):395-398
pubmed: 33536231
Forensic Sci Int. 2014 Jul;240:1-8
pubmed: 24769343
Ann Med. 2022 Dec;54(1):2861-2875
pubmed: 36263866
J Anal Toxicol. 2001 May-Jun;25(4):245-9
pubmed: 11386637

Auteurs

Joseph Pergolizzi (J)

Pain Medicine, Nema Research, Inc., Naples, USA.

Jo Ann K LeQuang (JAK)

Healthcare Policy, Nema Research, Inc., Naples, USA.

Peter Magnusson (P)

School of Medical Sciences, Örebro University, Örebro, SWE.

Thomas L Miller (TL)

Clinical Development, Enalare Therapeutics, Inc., Princeton, USA.

Frank Breve (F)

Pharmacy, Temple University, Philadelphia, USA.

Giustino Varrassi (G)

Pain Medicine, Paolo Procacci Foundation, Rome, ITA.

Classifications MeSH